Login to Your Account



Threshold Pharmaceuticals' Phase III Drills Down on Sarcoma

By Catherine Shaffer


Monday, October 3, 2011
Threshold Pharmaceuticals Inc. is wasting no time launching a Phase III randomized trial of its sarcoma drug, TH-302, following a successful end-of-Phase-II meeting with the FDA, resulting in a special protocol assessment.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription